AvalehtGLSWQ • OTCMKTS
add
Gelesis
Viimane sulgemishind
0,00 $
Turuväärtus
7,33 tuh USD
P/E suhe
-
Dividendimäär
-
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(USD) | juuni 2023info | Y/Y muutus |
---|---|---|
Käive | 1,11 mln | — |
Põhitegevusega seonduv kulu | 10,60 mln | — |
Puhastulu | −7,68 mln | — |
Puhaskasumimarginaal | −693,86 | — |
Puhaskasum aktsia kohta | — | — |
EBITDA | −7,93 mln | — |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(USD) | juuni 2023info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 7,91 mln | — |
Kogu vara | 95,88 mln | — |
Kõik kohustused | 114,50 mln | — |
Kogu omakapital | −18,62 mln | — |
Emiteeritud aktsiate arv | 73,34 mln | — |
Hinna ja väärtuse suhe P/B | −0,00 | — |
Varade tasuvus | −25,68% | — |
Kapitali tasuvus | −55,33% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(USD) | juuni 2023info | Y/Y muutus |
---|---|---|
Puhastulu | −7,68 mln | — |
Põhitegevuse rahakäive | 617,00 tuh | — |
Investeeringute raha | −18,00 tuh | — |
Finantseerimise raha | 4,17 mln | — |
Raha ja raha ekvivalentide muutus | 4,81 mln | — |
Tasuta rahavoog | 3,82 mln | — |
Teave
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Gelesis Holdings, Inc. together with its two affiliates, filed for voluntary Chapter 7 liquidation in the United States Bankruptcy Court for the District of Delaware on October 30, 2023. The debtor listed its assets among the 50 and the $100 million and liabilities of $44.34 million. The Debtor is represented by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP as counsel. Wikipedia
Asutatud
2006
Veebisait
Töötajate arv
93